By Application
Hot products 
-
Rabbit Anti-B2M Recombinant Antibody (CBYY-0059) (CBMAB-0059-YY)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503417) (CBMAB-V208-1369-FY)
-
Mouse Anti-AGK Recombinant Antibody (V2-258056) (CBMAB-M0989-FY)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Mouse Anti-ATP1B3 Recombinant Antibody (1E9) (CBMAB-A4021-YC)
-
Rabbit Anti-ALDOA Recombinant Antibody (D73H4) (CBMAB-A2314-YC)
-
Mouse Anti-BRCA2 Recombinant Antibody (CBYY-1728) (CBMAB-2077-YY)
-
Mouse Anti-CD24 Recombinant Antibody (HIS50) (CBMAB-C10123-LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-BLNK Recombinant Antibody (CBYY-0623) (CBMAB-0626-YY)
-
Mouse Anti-EGR1 Recombinant Antibody (CBWJZ-100) (CBMAB-Z0289-WJ)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-ASB9 Recombinant Antibody (1D8) (CBMAB-A0529-LY)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Rat Anti-CD63 Recombinant Antibody (7G4.2E8) (CBMAB-C8725-LY)
-
Rabbit Anti-Acetyl-Histone H4 (Lys16) Recombinant Antibody (V2-623415) (CBMAB-CP1021-LY)
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
-
Mouse Anti-dsRNA Recombinant Antibody (2) (CBMAB-D1807-YC)
-
Mouse Anti-CORO1A Recombinant Antibody (4G10) (V2LY-1206-LY806)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
Loading...
Compare
